Researchers have found that a small molecule, Nutlin-3a, an antagonist of MDM2 protein, stimulates the signaling pathway of another protein, p53. By this way, it induces cell death and senescence (loss of proliferative capacity) in brain cancer, a fact that slows its growth. These results open the door for MDM2 agonists as new treatments for glioblastomas.